Patents by Inventor Malla Padidam
Malla Padidam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230364225Abstract: Provided are pharmaceutical/veterinary compositions including (1) an effective amount of nucleic acid molecule(s) comprising nucleotide sequences encoding (a) disease-causing agent-associated antigen(s) and (b) innate trained immunity immunomodulator(s), and (2) an effective amount of either (a) calcium phosphate nanoparticles associated with the molecules that detectably enhance cellular uptake of the molecules, immunogenicity of the composition, or both, or (b) a nonpathogenic bacterial vector that contains the molecules and detectably promotes delivery of the nucleic acid molecules. Immunomodulators can include signal transducing activator protein sequences, antigen(s) can include immune cell targeting sequences (e.g., alphaherpesvirus glycoprotein D sequences) or internal targeting sequences (such as polyubiquitin sequences), and expression products can include checkpoint inhibitors.Type: ApplicationFiled: December 9, 2022Publication date: November 16, 2023Inventors: Lorraine Keller, Malla Padidam
-
Publication number: 20220389035Abstract: The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular neuropathies.Type: ApplicationFiled: July 17, 2020Publication date: December 8, 2022Inventors: Robert Eugene HORMANN, Malla PADIDAM
-
Patent number: 11130787Abstract: This invention provides new compositions comprising nucleotide sequence(s) encoding alphaherpesvirus glycoprotein D protein(s) (gDP(s)) and antigen(s) that induce immune responses. Such sequences typically encode gDP:antigen fusion proteins and typically also include feature(s) that significantly enhance immune responses such as (a) sequences encoding ITIC signal transducing adaptor proteins, e.g., SLAM-associated proteins (SAPs), Ewing's sarcoma-associated transcript 2 proteins, or both, or non-gDP checkpoint inhibitor(s); (b) sequences encoding antigen-associated targeting sequences, e.g., polyubiquitin sequences; (c) deimmunized/modified antigen-encoding sequences; (d) gDP(s) with modified sequence(s); (e) expression-enhancing introns; (f) transfection-facilitating agents; or (g) combinations thereof.Type: GrantFiled: June 30, 2020Date of Patent: September 28, 2021Assignee: MBF Therapeutics, Inc.Inventors: Lorraine Keller, Malla Padidam
-
Publication number: 20200325182Abstract: This invention provides new compositions comprising nucleotide sequence(s) encoding alphaherpesvirus glycoprotein D protein(s) (gDP(s)) and antigen(s) that induce immune responses. Such sequences typically encode gDP:antigen fusion proteins and typically also include feature(s) that significantly enhance immune responses such as (a) sequences encoding ITIC signal transducing adaptor proteins, e.g., SLAM-associated proteins (SAPs), Ewing's sarcoma-associated transcript 2 proteins, or both, or non-gDP checkpoint inhibitor(s); (b) sequences encoding antigen-associated targeting sequences, e.g., polyubiquitin sequences; (c) deimmunized/modified antigen-encoding sequences; (d) gDP(s) with modified sequence(s); (e) expression-enhancing introns; (f) transfection-facilitating agents; or (g) combinations thereof.Type: ApplicationFiled: June 30, 2020Publication date: October 15, 2020Inventors: Lorraine Keller, Malla Padidam
-
Patent number: 10648003Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: GrantFiled: June 8, 2018Date of Patent: May 12, 2020Assignee: Intrexon CorporationInventor: Malla Padidam
-
Publication number: 20180346934Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: ApplicationFiled: June 8, 2018Publication date: December 6, 2018Inventor: Malla PADIDAM
-
Patent number: 10081817Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: GrantFiled: October 31, 2016Date of Patent: September 25, 2018Assignee: Intrexon CorporationInventor: Malla Padidam
-
Publication number: 20170114370Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: ApplicationFiled: October 31, 2016Publication date: April 27, 2017Inventor: Malla PADIDAM
-
Publication number: 20150275232Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recominbination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis pType: ApplicationFiled: April 16, 2015Publication date: October 1, 2015Applicant: Intrexon CorporationInventor: Malla PADIDAM
-
Patent number: 9034650Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: GrantFiled: February 2, 2005Date of Patent: May 19, 2015Assignee: Intrexon CorporationInventor: Malla Padidam
-
Publication number: 20080020465Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: ApplicationFiled: August 20, 2007Publication date: January 24, 2008Inventor: Malla Padidam
-
Publication number: 20060172377Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: ApplicationFiled: February 2, 2005Publication date: August 3, 2006Inventor: Malla Padidam
-
Patent number: 6852907Abstract: The invention describes methods for producing plant resistance to a ssDNA virus, particularly a geminivirus such as mastrevirus, curtovirus or begomovirus. The method comprises introducing a ssDNA-binding protein of the Inoviridae virus into the plant, and includes a phage coat protein, particularly, a coliphage gene 5 protein. The invention also describes a transgenic plant comprising a gene that expresses the ssDNA-binding protein and vectors for expressing the protein in plants.Type: GrantFiled: March 3, 1999Date of Patent: February 8, 2005Assignee: The Scripps Research InstituteInventors: Malla Padidam, Roger N. Beachy, Claude M. Fauquet
-
Publication number: 20020155540Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to methods to reduce or eliminate transcriptional interference between two or more tandemly arranged genes within a host cell.Type: ApplicationFiled: February 13, 2002Publication date: October 24, 2002Inventor: Malla Padidam